Author + information
Recent evidence demonstrated that the circulating levels of adipokine are related to the presence of heart failure secondary to ischemic heart disease and dilated cardiomyopathy (DCM). However, the plasma levels of Chemerin in patients with DCM have yet to be investigated.
The present study enrolled 109 DCM patients with typical symptoms of heart failure and 60 healthy controls and measured plasma levels of Chemerin, IL-6 and TNF-α using enzyme-linked immunosorbent assay. Left ventricular end-diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) were measured using a GE ViVid E7 ultrasonography machine.
Plasma Chemerin, IL-6 and TNF-α levels were significantly higher in DCM patients compared to the control group. A correlation analysis revealed that plasma Chemerin levels were positively correlated with the levels of IL-6 (R=0.270, P=0.004), TNF-α (R=0.302, P=0.001), C-reactive protein (CRP) (R=0.256, P=0.004), N-terminal pro-brain natriuretic peptide (NT-proBNP) (R=0.386, P=0.000), and LVEDD (R=0.212, P=0.027) but negatively correlated with LVEF (R=-0.543, P=0.000). Furthermore, Chemerin (OR 1.102, 95% CI 1.052 to 1.153; p=0.000) was independently associated with the presence of DCM before NT-proBNP was added in the multivariable regression model.
The results indicate that Chemerin is a novel biomarker of DCM.